EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Sudden Death Risk Assessment in Hypertrophic Cardiomyopathy Across the Lifespan

Ahmad Al Samarraie, Adrian Petzl, Julia Cadrin-Tourigny, Rafik Tadros

Heart Failure Clinics · 2025

DOI: 10.1016/j.hfc.2025.07.002 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Heart Failure Clinics, 2025. Verfasst von Ahmad Al Samarraie und 3 weiteren Autor:innen. Beteiligte Einrichtung: Cardiovascular Genetics Centre, Montreal Heart Institute, 5000 Bélanger, Montreal, Quebec H1T 1C8, Canada; Faculty of Medicine, Université de Montréa…. Hauptthemen laut MEDLINE: Cardiomyopathy, Hypertrophic, Death, Sudden, Cardiac. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 78 Literaturangaben. Gefördert von: Canadian Institutes of Health Research, Canada Research Chairs.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Hypertrophic cardiomyopathy (HCM) is the most prevalent inherited cardiac disease. Since the modern description of HCM more than seven decades ago, great focus has been placed on preventing its most catastrophic complication: sudden cardiac death (SCD). Implantable cardioverter-defibrillators (ICD) have been recognized to provide effective prophylactic therapy. Over the years, two leading societies, the European Society of Cardiology (ESC) and the American Heart Association/American College of Cardiology (AHA/ACC), have proposed risk stratification models to assess SCD in adults. European guidelines rely on a risk calculator, the HCM Risk-SCD, while American guidelines propose a stand-alone risk factor approach. Recently, risk prediction models were also developed in the pediatric population. This article reviews the latest recommendations on the risk stratification of SCD in HCM and summarises current indications for ICD use.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cardiomyopathy, HypertrophicDeath, Sudden, CardiacHumansRisk AssessmentUnited StatesEuropeDefibrillators, ImplantableRisk Factors

Stichwörter der Autor:innen

Hypertrophic cardiomyopathyImplantable cardioverter-defibrillatorRisk scoreRisk stratificationSudden cardiac death

Autor:innen und Institutionen

  • Cardiovascular Genetics Centre, Montreal Heart Institute, 5000 Bélanger, Montreal, Quebec H1T 1C8, Canada; Faculty of Medicine, Université de Montréal, 2900 Edouard Montpetit, Montreal, Quebec H3T 1J4, Canada.
  • Cardiovascular Genetics Centre, Montreal Heart Institute, 5000 Bélanger, Montreal, Quebec H1T 1C8, Canada; Faculty of Medicine, Université de Montréal, 2900 Edouard Montpetit, Montreal, Quebec H3T 1J4, Canada. Electroni…

Förderung

  • Canadian Institutes of Health Research
  • Canada Research Chairs

Zitieren

APA

Al Samarraie, A., Petzl, A., Cadrin-Tourigny, J., & Tadros, R. (2025). Sudden Death Risk Assessment in Hypertrophic Cardiomyopathy Across the Lifespan. Heart Failure Clinics. https://doi.org/10.1016/j.hfc.2025.07.002

Vancouver

Al Samarraie A, Petzl A, Cadrin-Tourigny J, Tadros R. Sudden Death Risk Assessment in Hypertrophic Cardiomyopathy Across the Lifespan. Heart Failure Clinics. 2025. doi:10.1016/j.hfc.2025.07.002

BibTeX
@article{AlSamarraie2025,
  author = {Al Samarraie, Ahmad and Petzl, Adrian and Cadrin-Tourigny, Julia and Tadros, Rafik},
  title = {Sudden Death Risk Assessment in Hypertrophic Cardiomyopathy Across the Lifespan},
  journal = {Heart Failure Clinics},
  year = {2025},
  doi = {10.1016/j.hfc.2025.07.002}
}
Kostenlos starten →